menu
    • menu
    [{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Cedirogant","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inventiva Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cedirogant","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inventiva Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva Pharma \/ AbbVie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Cedirogant

    Menu

    Cedirogant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inventiva Pharma

                            France arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Inventiva Pharma

                            France arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cedirogant

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Inventiva Provides An Update On The Development Of Cedirogant By AbbVie

                            Details : Cedirogant (ABBV-157) is an orally available retinoic acid-related orphan receptor gamma (RORγ) inverse-agonist, small molecule for the treatment of chronic plaque psoriasis.

                            Product Name : ABBV-157

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 31, 2022

                            Lead Product(s) : Cedirogant

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inventiva Pharma

                            France arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Inventiva Pharma

                            France arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cedirogant

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : $4.3 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Inventiva Receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

                            Details : It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157), an oral RORγ inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.

                            Product Name : ABBV-157

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 31, 2022

                            Lead Product(s) : Cedirogant

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : $4.3 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth